Two patients developed APS, as previously reported (12), implying that APS should not only be considered as a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) but should also be tested for anti-GFAP antibodies. This evidence concerns the gene GFAP and neuromyelitis optica.